Comparing Avivagen (OTCMKTS:VIVXF) and Capricor Therapeutics (NASDAQ:CAPR)

Avivagen (OTCMKTS:VIVXF) and Capricor Therapeutics (NASDAQ:CAPR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Insider & Institutional Ownership

21.7% of Capricor Therapeutics shares are owned by institutional investors. 2.1% of Avivagen shares are owned by company insiders. Comparatively, 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Avivagen and Capricor Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avivagen	N/A	N/A	N/A	($0.04)	N/A
Capricor Therapeutics	$22.27 million	77.91	-$105.04 million	($2.32)	-12.91

Avivagen has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Avivagen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Avivagen and Capricor Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avivagen	0	0	0	0	0.00
Capricor Therapeutics	1	0	9	0	2.80

Capricor Therapeutics has a consensus target price of $48.36, suggesting a potential upside of 61.43%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Avivagen.

Profitability

This table compares Avivagen and Capricor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avivagen	N/A	N/A	N/A
Capricor Therapeutics	N/A	-59.27%	-48.65%

Summary

Capricor Therapeutics beats Avivagen on 6 of the 9 factors compared between the two stocks.

About Avivagen

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.